Scilex Q4 2025 Earnings Report

Scilex EPS Results

• Actual EPS: -$4.60
• Consensus EPS: -$0.47
• Beat/Miss: Missed by -$4.13
• One Year Ago EPS: N/A

Scilex Revenue Results

• Actual Revenue: $4.79 million
• Expected Revenue: $12.10 million
• Beat/Miss: Missed by -$7.31 million
• YoY Revenue Growth: N/A

Scilex Announcement Details

• Quarter: Q4 2025
• Date: 4/10/2026
• Time: Before Market Opens
• Conference Call Date: Friday, April 10, 2026
• Conference Call Time: 8:00AM ET

Scilex (NASDAQ:SCLX) Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.